{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T03:55:09Z","timestamp":1768622109802,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.cgh.2016.05.010","type":"journal-article","created":{"date-parts":[[2016,5,14]],"date-time":"2016-05-14T20:30:19Z","timestamp":1463257819000},"page":"1302-1309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Appropriateness of Testing for Anti\u2013Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of\u00a0Results"],"prefix":"10.1016","volume":"14","author":[{"given":"Gil Y.","family":"Melmed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter M.","family":"Irving","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilaad G.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia L.","family":"Kozuch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando S.","family":"Velayos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard","family":"Baidoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miles P.","family":"Sparrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Bressler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam S.","family":"Cheifetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shane M.","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura E.","family":"Raffals","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Vande Casteele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane R.","family":"Mould","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fred","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marla","family":"Dubinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Sandborn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corey A.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2016.05.010_bib1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/ajg.2010.392","article-title":"The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?","volume":"106","author":"D'Haens","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2016.05.010_bib2","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1053\/j.gastro.2014.07.022","article-title":"Crohn's disease evaluation and treatment: clinical decision tool","volume":"147","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2016.05.010_bib3","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1053\/j.gastro.2009.06.061","article-title":"Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab","volume":"137","author":"Sandborn","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2016.05.010_bib4","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1053\/j.gastro.2008.07.069","article-title":"Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study","volume":"135","author":"Feagan","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2016.05.010_bib5","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/j.gastro.2013.09.032","article-title":"Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis","volume":"146","author":"Feagan","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2016.05.010_bib6","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1136\/gutjnl-2014-307883","article-title":"The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease","volume":"64","author":"Vande Casteele","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2016.05.010_bib7","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1136\/gutjnl-2014-307882","article-title":"Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial","volume":"65","author":"Baert","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2016.05.010_bib8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ajg.2012.363","article-title":"Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis","volume":"108","author":"Nanda","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2016.05.010_bib9","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1053\/j.gastro.2014.10.011","article-title":"Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis","volume":"148","author":"Hazlewood","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2016.05.010_bib10","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ajg.2010.9","article-title":"Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease","volume":"105","author":"Afif","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2016.05.010_bib11","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1097\/MIB.0000000000000137","article-title":"Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease","volume":"20","author":"Singh","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2016.05.010_bib12","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1136\/gutjnl-2012-304094","article-title":"Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial","volume":"63","author":"Cornillie","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2016.05.010_bib13","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1097\/MIB.0000000000000156","article-title":"Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study","volume":"20","author":"Vaughn","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2016.05.010_bib14","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","article-title":"Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease","volume":"148","author":"Vande Casteele","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2016.05.010_bib15","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/j.1572-0241.2007.01638.x","article-title":"Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease","volume":"103","author":"Ainsworth","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2016.05.010_bib16","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/MIB.0000000000000202","article-title":"Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse","volume":"21","author":"Papamichael","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2016.05.010_bib17","first-page":"E6","article-title":"Linking evidence-based medicine therapeutic summary measures to clinical decision analysis","volume":"2","author":"Djulbegovic","year":"2000","journal-title":"MedGenMed"},{"key":"10.1016\/j.cgh.2016.05.010_bib18","series-title":"The RAND\/UCLA Appropriateness Method. Clinical practice guideline development: methodology perspectives","author":"Brook","year":"1994"},{"key":"10.1016\/j.cgh.2016.05.010_bib19","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.cgh.2010.04.023","article-title":"The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all","volume":"8","author":"Melmed","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2016.05.010_bib20","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/ibd.22920","article-title":"Setting priorities for comparative effectiveness research in inflammatory bowel disease: results of an international provider survey, expert RAND panel, and patient focus groups","volume":"18","author":"Cheifetz","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2016.05.010_bib21","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/apt.12869","article-title":"Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease","volume":"40","author":"Mazor","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2016.05.010_bib22","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cgh.2013.07.010","article-title":"Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases","volume":"12","author":"Roblin","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2016.05.010_bib23","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.cgh.2012.10.020","article-title":"Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease","volume":"11","author":"Ben-Horin","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2016.05.010_bib24","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1136\/gutjnl-2013-305279","article-title":"Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial","volume":"63","author":"Steenholdt","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2016.05.010_bib25","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.cgh.2012.12.035","article-title":"A\u00a0test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab","volume":"11","author":"Velayos","year":"2013","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356516301951?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356516301951?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:19:15Z","timestamp":1761542355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356516301951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S1542356516301951"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2016.05.010","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Appropriateness of Testing for Anti\u2013Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of\u00a0Results","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2016.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the AGA Institute","name":"copyright","label":"Copyright"}]}}